D47.1 ICD-10-CM Code: Chronic myeloproliferative disease
D47.1 maps to CMS-HCC V28 21. A source-labeled RAF reference is available. Confirm the documented diagnosis and applicable coding requirements. MEAT criteria · RAF Calculator · HCC Buddy coding tools
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Neoplasms (C00-D49) / Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes (D37-D48)
D47.1
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceChronic myeloproliferative disease
A group of blood disorders where the bone marrow produces too many blood cells over a long period of time, leading to thickened blood and potential clotting problems. This is a chronic condition that requires ongoing monitoring and management.
Buddy Insight
Chronic myeloproliferative disease encompasses a group of clonal bone marrow disorders characterized by overproduction of one or more myeloid cell lines.
CMS-HCC V28
MappedHCC 21
Coefficient HCC 21: 0.671 (Community Non-Dual Aged (CNA))
CMS-HCC V24
HistoricalHistorical
Not used for CY2026 payment
ACA/HHS
MappedHCC 075
Code-level coefficient reference
ESRD/PACE
MappedHCC 48
Code-level coefficient reference
RXHCC
MappedHCC 21
Code-level coefficient reference
Code Book Path
Inclusion Terms
Official- Chronic neutrophilic leukemia
- Myeloproliferative disease, unspecified
Excludes 2
OfficialNo Excludes 2 notes are included in this display for D47.1. Check the code and parent instructions in the Code Book.
Related Codes
Includes
OfficialNo Includes notes are included in this display for D47.1. Check the code and parent instructions in the Code Book.
Excludes 1
Official- atypical chronic myeloid leukemia BCR/ABL-negative (C92.2-)
- chronic myeloid leukemia BCR/ABL-positive (C92.1-)
- myelofibrosis NOS (D75.81)
- myelophthisic anemia (D61.82)
- myelophthisis (D61.82)
- secondary myelofibrosis NOS (D75.81)
- neoplasms of unspecified behavior (D49.-)Inherited from D37-D48
Code First
OfficialNo Code First sequencing instructions are included in this display for D47.1. Check the code and parent instructions in the Code Book.
Use Additional
OfficialNo Use Additional Code instructions are included in this display for D47.1. Check the code and parent instructions in the Code Book.
Code Also
OfficialNo Code Also instructions are included in this display for D47.1. Check the code and parent instructions in the Code Book.
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →
Is D47.1 an HCC code?
Yes. D47.1 (Chronic myeloproliferative disease) maps to HCC 21, Lymphoma and Other Cancers under the CMS-HCC V28 risk adjustment model, with a source-labeled community non-dual aged reference coefficient of 0.671. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes. It is billable for payment year 2026.
Coder answer: D47.1 is billable and maps to V28 HCC 21, Lymphoma and Other Cancers. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.
- Code
- D47.1
- Description
- Chronic myeloproliferative disease
- HCC (V28)
- HCC 21 — Lymphoma and Other Cancers
- RAF reference coefficient
- 0.671
- Billable
- Yes
- Payment year
- 2026
HCC Category Mapping
These are source-labeled model coefficients, not member totals. A category may still be removed by hierarchy or model cleanup rules. Weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member context, hierarchy and cleanup rules, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains available for historical review.
Work D47.1 in the Code Book — tabular path, V28 RAF reference, and MEAT checklist →
MEAT review for D47.1
For D47.1, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Coder workflow notes
Get the V28 mapping + MEAT cheat sheet
One printable reference: check representative V28 mappings and the documentation reminders your note needs. Free, no card.
Free PDF. No card. Unsubscribe anytime.
What This Code Means
D47.1 is the ICD-10-CM diagnosis code for chronic myeloproliferative disease. A group of blood disorders where the bone marrow produces too many blood cells over a long period of time, leading to thickened blood and potential clotting problems. This is a chronic condition that requires ongoing monitoring and management. D47.1 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes (d37-d48).
Under the CMS-HCC V28 risk adjustment model, D47.1 maps to Lymphoma and Other Cancers (HCC 21) with a source-labeled community, non-dual, aged reference coefficient of 0.671. No V24 mapping is shown for D47.1; use the applicable model and payment year when reviewing the V28 mapping. For CY2026 non-PACE Medicare Advantage, CMS uses 100% of the 2024 CMS-HCC model (V28). PACE uses a separate model blend. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes.
Verify the specific type of myeloproliferative disease (polycythemia vera, essential thrombocythemia, primary myelofibrosis) as these may have more specific codes available under D47.1x. For D47.1, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, source-labeled coefficient references, and MEAT documentation criteria for D47.1 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Verify the specific type of myeloproliferative disease (polycythemia vera, essential thrombocythemia, primary myelofibrosis) as these may have more specific codes available under D47.1x
- •Ensure documentation supports the chronic nature of the condition and distinguish from acute leukemias or other neoplastic disorders that would require different coding
Clinical Significance
Chronic myeloproliferative disease encompasses a group of clonal bone marrow disorders characterized by overproduction of one or more myeloid cell lines. This includes conditions that do not meet specific criteria for polycythemia vera, essential thrombocythemia, or primary myelofibrosis, and these patients face risks of thrombosis, hemorrhage, and disease transformation.
Documentation Requirements
- ✓Documentation should specify the myeloproliferative features including which cell lines are predominantly affected, bone marrow biopsy findings, cytogenetic analysis, and molecular markers (JAK2, CALR, MPL mutations).
- ✓Document peripheral blood counts, spleen size, and any constitutional symptoms.
- ✓Clarify why the condition does not meet criteria for more specific myeloproliferative neoplasm subtypes.
Excludes 1, Do NOT code together
Commonly Confused Codes
- •D45 (polycythemia vera) has specific diagnostic criteria centering on erythrocytosis.
- •D47.3 (essential thrombocythemia) centers on thrombocytosis.
- •D47.4 (osteomyelofibrosis) involves bone marrow fibrosis.
- •C92.10 (chronic myeloid leukemia, BCR/ABL-positive) requires the Philadelphia chromosome.
- •D46.9 (myelodysplastic syndrome, unspecified) is a different category of bone marrow disorder.